Intas sells ChrysCapital's stake to Temasek
Temasek has acquired a 10.6 per cent equity stake in Intas.
New Delhi, November 11, 2014: Intas Pharmaceuticals Ltd has announced that the Singapore based investment firm, Temasek, has acquired a 10.6 per cent stake in the company by secondary purchase of shares from ChrysCapital.
Intas is a leading, vertically-integrated global pharmaceutical company from India, having end-to-end capabilities of formulation development, manufacturing and marketing along with backward integration of APIs. With three decades of progressive strategies, productive R&D, biotechnological expertise and investments in ten advanced manufacturing facilities across the globe, Intas has emerged as one of the fastest-growing pharmaceutical organisations in the world.
Intas is investing significant resources to build a pipeline of novel drug delivery technology based products. It has become the first company in the world to launch a Nanosomal Docetaxel Lipid Suspension (NDLS), DoceAqualip, designed to significantly reduce the hypersensitivity of the drug amongst the patients.
With the recent investment, Temasek has deepened its exposure to India's pharmaceutical industry.